Literature DB >> 11342300

What can we learn from leukemia as for the process of lineage commitment in hematopoiesis?

C A Schmidt1, G K Przybylski.   

Abstract

Most contemporary models of hematopoiesis assume lineage fidelity of early progenitor cells. Along with this concept normal hematopoietic cells and the majority of leukemias express exclusively myeloid or lymphoid specific antigens. On the other hand, growing evidence exists challenging the lineage fidelity model. Chronic myeloid leukemia (CML) in the blast crisis may switch to acute lymphoblastic leukemia (ALL) and as a result of the chemotherapy ALL may converse to acute myeloid leukemia (AML). Furthermore, a substantial portion of leukemia cases, named acute mixed-lineage leukemia (AMLL), show simultaneous expression of both myeloid and lymphoid antigens. Immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements, correlating with myeloid-lymphoid immunophenotype in AMLL, support the hypothesis of lineage infidelity of early progenitor cells, rather than the aberrant antigen expression. Based on a detailed characterization of AMLL we present a modified model of a "common myeloid/lymphoid progenitor cell". This hypothetical very early hematopoietic progenitor cell shows a transient expression of myeloid and B- or T-lymphoid antigen and may also have rearranged its Ig and/or TCR genes. Subsequently, myeloid or lymphoid markers are downregulated and the hematopoietic cell enters either myeloid, T-lymphoid or B-lymphoid differentiation pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11342300     DOI: 10.3109/08830180109056725

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  8 in total

Review 1.  Leukemia: stem cells, maturation arrest, and differentiation therapy.

Authors:  Stewart Sell
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

2.  Construction of protein profile classification model and screening of proteomic signature of acute leukemia.

Authors:  Yun Xu; Jiacai Zhuo; Yonggang Duan; Benhang Shi; Xuhong Chen; Xiaoli Zhang; Liang Xiao; Jin Lou; Ruihong Huang; Qiongli Zhang; Xin Du; Ming Li; Daping Wang; Dunyun Shi
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

3.  Constitutively active beta-catenin confers multilineage differentiation potential on lymphoid and myeloid progenitors.

Authors:  Yoshihiro Baba; Karla P Garrett; Paul W Kincade
Journal:  Immunity       Date:  2005-12       Impact factor: 31.745

4.  Erythroleukemia relapsing as precursor B-cell lymphoblastic leukemia.

Authors:  Borae G Park; Chan-Jeoung Park; Seongsoo Jang; Eul Ju Seo; Hyun-Sook Chi; Jung-Hee Lee
Journal:  Korean J Lab Med       Date:  2011-04

Review 5.  Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?

Authors:  Axel Schulenburg; Katharina Blatt; Sabine Cerny-Reiterer; Irina Sadovnik; Harald Herrmann; Brigitte Marian; Thomas W Grunt; Christoph C Zielinski; Peter Valent
Journal:  J Hematol Oncol       Date:  2015-02-25       Impact factor: 17.388

6.  A functional polymorphism in the CEBPE gene promoter influences acute lymphoblastic leukemia risk through interaction with the hematopoietic transcription factor Ikaros.

Authors:  J L Wiemels; A J de Smith; J Xiao; S-T Lee; M O Muench; M E Fomin; M Zhou; H M Hansen; A Termuhlen; C Metayer; K M Walsh
Journal:  Leukemia       Date:  2015-09-16       Impact factor: 11.528

7.  Gata3 restrains B cell proliferation and cooperates with p18INK4c to repress B cell lymphomagenesis.

Authors:  Shiqin Liu; Ho Lam Chan; Feng Bai; Jinshan Ma; Alexandria Scott; David J Robbins; Anthony J Capobianco; Ping Zhu; Xin-Hai Pei
Journal:  Oncotarget       Date:  2016-09-27

Review 8.  Mechanisms of Immunosuppressive Tumor Evasion: Focus on Acute Lymphoblastic Leukemia.

Authors:  Silvia Jiménez-Morales; Ivan Sammir Aranda-Uribe; Carlos Jhovani Pérez-Amado; Julian Ramírez-Bello; Alfredo Hidalgo-Miranda
Journal:  Front Immunol       Date:  2021-11-18       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.